Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Coherus BioSciences stock

Own Coherus BioSciences stock in just a few minutes.

Coherus BioSciences, Inc is a biotechnology business based in the US. Coherus BioSciences shares (CHRS) are listed on the NASDAQ and all prices are listed in US Dollars. Coherus BioSciences employs 317 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Coherus BioSciences

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CHRS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Coherus BioSciences share price

Use our graph to track the performance of CHRS stocks over time.

Coherus BioSciences shares at a glance

Information last updated 2021-04-28.
52-week range$13.53 - $22.22
50-day moving average $14.80
200-day moving average $16.97
Wall St. target price$27.63
PE ratio 9.0887
Dividend yield N/A (0%)
Earnings per share (TTM) $1.62

Buy Coherus BioSciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Coherus BioSciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Coherus BioSciences under- or over-valued?

Valuing Coherus BioSciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Coherus BioSciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Coherus BioSciences's P/E ratio

Coherus BioSciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 9x. In other words, Coherus BioSciences shares trade at around 9x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Coherus BioSciences's EBITDA

Coherus BioSciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $159.2 million.

The EBITDA is a measure of a Coherus BioSciences's overall financial performance and is widely used to measure a its profitability.

Coherus BioSciences financials

Revenue TTM $475.8 million
Operating margin TTM 32.85%
Gross profit TTM $295.4 million
Return on assets TTM 15.63%
Return on equity TTM 68.49%
Profit margin 27.79%
Book value $3.88
Market capitalisation $1.1 billion

TTM: trailing 12 months

Shorting Coherus BioSciences shares

There are currently 13.4 million Coherus BioSciences shares held short by investors – that's known as Coherus BioSciences's "short interest". This figure is 3% down from 13.8 million last month.

There are a few different ways that this level of interest in shorting Coherus BioSciences shares can be evaluated.

Coherus BioSciences's "short interest ratio" (SIR)

Coherus BioSciences's "short interest ratio" (SIR) is the quantity of Coherus BioSciences shares currently shorted divided by the average quantity of Coherus BioSciences shares traded daily (recently around 956726.87099073). Coherus BioSciences's SIR currently stands at 14.03. In other words for every 100,000 Coherus BioSciences shares traded daily on the market, roughly 14030 shares are currently held short.

However Coherus BioSciences's short interest can also be evaluated against the total number of Coherus BioSciences shares, or, against the total number of tradable Coherus BioSciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Coherus BioSciences's short interest could be expressed as 0.18% of the outstanding shares (for every 100,000 Coherus BioSciences shares in existence, roughly 180 shares are currently held short) or 0.2642% of the tradable shares (for every 100,000 tradable Coherus BioSciences shares, roughly 264 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Coherus BioSciences.

Find out more about how you can short Coherus BioSciences stock.

Coherus BioSciences share dividends

We're not expecting Coherus BioSciences to pay a dividend over the next 12 months.

Coherus BioSciences share price volatility

Over the last 12 months, Coherus BioSciences's shares have ranged in value from as little as $13.53 up to $22.2166. A popular way to gauge a stock's volatility is its "beta".

CHRS.US volatility(beta: 1.09)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Coherus BioSciences's is 1.091. This would suggest that Coherus BioSciences's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Coherus BioSciences overview

Coherus BioSciences, Inc. , a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its product candidate pipeline includes biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar; and CHS-131, a once-daily oral drug candidate for non-alcoholic steatohepatitis and other metabolic conditions. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site